<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772109</url>
  </required_header>
  <id_info>
    <org_study_id>FID31</org_study_id>
    <nct_id>NCT00772109</nct_id>
  </id_info>
  <brief_title>Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults</brief_title>
  <official_title>Lot Consistency, Immunogenicity, and Safety Study of Three Lots of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test lot consistency of three different manufacturing lots and to
      generate safety and immunogenicity data of the investigational vaccine administered via the
      ID route.

      Primary Objective:

        -  To demonstrate lot consistency of the Fluzone ID manufacturing process.

        -  To provide information concerning the immune response of Fluzone ID.

      Secondary Objectives:

      Safety

        -  To describe the safety profile of subjects who receive of Fluzone ID.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three lots of the investigational Fluzone vaccine with the 2008/2009 Northern Hemisphere
      formulation will be administered intradermally (ID) using the Becton Dickinson Micro
      Injection System.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines</measure>
    <time_frame>Baseline (Day 0) and 28 Days post-vaccination</time_frame>
    <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved Seroconversion Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</measure>
    <time_frame>28 Days post-vaccination</time_frame>
    <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and post-vaccination titer of ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum of four-fold increase 28 days post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Seroprotection Pre- and Post-vaccination With Either Fluzone ID or Fluzone IM</measure>
    <time_frame>Before and 28 Days post-vaccination</time_frame>
    <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.
Seroprotection was defined as a HAI antibody titer ≥ 1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 0 up to 7 Days post vaccination</time_frame>
    <description>Solicited injection site reactions: Ecchymosis, Erythema, Induration, Pain, Pruritus, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4292</enrollment>
  <condition>Orthomyxoviridae Infection</condition>
  <condition>Influenza</condition>
  <condition>Myxovirus Infection</condition>
  <arm_group>
    <arm_group_label>Fluzone Intradermal Vaccine Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose of Influenza intradermal vaccine Lot 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Intradermal Vaccine Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose of Influenza intradermal vaccine Lot 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Intradermal Vaccine Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a dose of Influenza intradermal vaccine Lot 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Intramuscular Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a dose of influenza intramuscular vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Fluzone Intradermal Vaccine Lot 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Fluzone Intradermal Vaccine Lot 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Fluzone Intradermal Vaccine Lot 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Vaccine USP Trivalent Types A and B</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Fluzone Intramuscular Vaccine</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Aged 18 to 64 years on the day of vaccination.

          -  Informed consent form signed and dated.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  For women of child bearing potential, avoid becoming pregnant (use of an effective
             method of contraception or abstinence) for at least 4 weeks prior to vaccination,
             until at least 4 weeks after vaccination.

        Exclusion Criteria :

          -  Known systemic hypersensitivity to any of the vaccine components or history of a
             life-threatening reaction to the trial vaccine or to a vaccine containing any of the
             same substances.

          -  For a woman of child-bearing potential: known pregnancy or positive serum/urine
             pregnancy test.

          -  Breast-feeding woman.

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or a medical procedure in the four weeks preceding the trial vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
             such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
             or long-term systemic corticosteroids therapy

          -  Chronic illness, at a stage that could interfere with trial conduct or completion, in
             the opinion of the investigator.

          -  Current alcohol abuse or drug addiction that may interfere with the subject's ability
             to comply with trial procedures.

          -  Receipt of blood or blood-derived products in the past 3 months that might interfere
             with the assessment of immune response.

          -  Receipt of any vaccination in the 4 weeks preceding the trial vaccination.

          -  Planned receipt of any vaccine in the 4 weeks following the trial vaccination.

          -  Previous vaccination against influenza in the past 6 months with the trial vaccine or
             another vaccine.

          -  Thrombocytopenia or bleeding disorder in the 3 weeks preceding inclusion.

          -  Subject deprived of freedom by an administrative or court order, or in an emergency
             setting, or hospitalized without his/her consent.

          -  Neoplastic disease or any hematologic malignancy, (except localized skin or prostate
             cancer that is stable at the time of vaccination in the absence of therapy, and
             subjects who have a history of neoplastic disease and who have been disease free for
             &gt;=5 years).

          -  Personal or family history of Guillain-Barré Syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <zip>19020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Castellana Gardens, Carolina</city>
        <zip>00983</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>October 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2008</study_first_posted>
  <results_first_submitted>July 16, 2011</results_first_submitted>
  <results_first_submitted_qc>July 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2011</results_first_posted>
  <disposition_first_submitted>March 31, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2010</disposition_first_posted>
  <last_update_submitted>April 12, 2016</last_update_submitted>
  <last_update_submitted_qc>April 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviruses</keyword>
  <keyword>Inactivated Split-virion influenza vaccine</keyword>
  <keyword>Fluzone®</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 13 through 30 October 2008 in 50 clinics in the US.</recruitment_details>
      <pre_assignment_details>A total of 4276 of the 4292 participants that met the inclusion and exclusion criteria enrolled were vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluzone Intradermal (ID) Vaccine Lot 1</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 1 on Day 0</description>
        </group>
        <group group_id="P2">
          <title>Fluzone Intradermal (ID) Vaccine Lot 2</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 2 on Day 0</description>
        </group>
        <group group_id="P3">
          <title>Fluzone Intradermal (ID) Vaccine Lot 3</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 3 on Day 0</description>
        </group>
        <group group_id="P4">
          <title>Fluzone Intramuscular (IM) Vaccine</title>
          <description>Participants received a dose of Fluzone Intramuscular (IM) vaccine on Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="956"/>
                <participants group_id="P2" count="953"/>
                <participants group_id="P3" count="955"/>
                <participants group_id="P4" count="1428"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="935"/>
                <participants group_id="P2" count="934"/>
                <participants group_id="P3" count="936"/>
                <participants group_id="P4" count="1397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Serious adverse event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluzone Intradermal (ID) Vaccine Lot 1</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 1 on Day 0</description>
        </group>
        <group group_id="B2">
          <title>Fluzone Intradermal (ID) Vaccine Lot 2</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 2 on Day 0</description>
        </group>
        <group group_id="B3">
          <title>Fluzone Intradermal (ID) Vaccine Lot 3</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 3 on Day 0</description>
        </group>
        <group group_id="B4">
          <title>Fluzone Intramuscular (IM) Vaccine</title>
          <description>Participants received a dose of Fluzone Intramuscular (IM) vaccine on Day 0</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="956"/>
            <count group_id="B2" value="953"/>
            <count group_id="B3" value="955"/>
            <count group_id="B4" value="1428"/>
            <count group_id="B5" value="4292"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="956"/>
                    <measurement group_id="B2" value="953"/>
                    <measurement group_id="B3" value="955"/>
                    <measurement group_id="B4" value="1428"/>
                    <measurement group_id="B5" value="4292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="13.41"/>
                    <measurement group_id="B2" value="42.8" spread="13.33"/>
                    <measurement group_id="B3" value="42.2" spread="13.78"/>
                    <measurement group_id="B4" value="42.5" spread="13.55"/>
                    <measurement group_id="B5" value="42.5" spread="13.5175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="611"/>
                    <measurement group_id="B2" value="619"/>
                    <measurement group_id="B3" value="594"/>
                    <measurement group_id="B4" value="899"/>
                    <measurement group_id="B5" value="2723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="361"/>
                    <measurement group_id="B4" value="529"/>
                    <measurement group_id="B5" value="1569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="956"/>
                    <measurement group_id="B2" value="953"/>
                    <measurement group_id="B3" value="955"/>
                    <measurement group_id="B4" value="1428"/>
                    <measurement group_id="B5" value="4292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines</title>
        <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay</description>
        <time_frame>Baseline (Day 0) and 28 Days post-vaccination</time_frame>
        <population>Geometric Mean Titers (GMTs) were analyzed in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Lot 1</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 1 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intradermal (ID) Vaccine Lot 2</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 2 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Intradermal (ID) Vaccine Lot 3</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 3 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Intramuscular (IM) Vaccine</title>
            <description>Participants received a dose of Fluzone Intramuscular (IM) vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines</title>
          <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay</description>
          <population>Geometric Mean Titers (GMTs) were analyzed in the per-protocol population</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="863"/>
                <count group_id="O2" value="856"/>
                <count group_id="O3" value="860"/>
                <count group_id="O4" value="1286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Pre-vaccination, N = 863, 856, 860, 1285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.50" lower_limit="21.58" upper_limit="25.60"/>
                    <measurement group_id="O2" value="25.27" lower_limit="23.16" upper_limit="27.58"/>
                    <measurement group_id="O3" value="25.29" lower_limit="23.20" upper_limit="27.56"/>
                    <measurement group_id="O4" value="24.84" lower_limit="23.16" upper_limit="26.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Post-vaccination, N = 863, 855, 861, 1283)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.56" lower_limit="172.67" upper_limit="205.92"/>
                    <measurement group_id="O2" value="185.59" lower_limit="169.81" upper_limit="202.83"/>
                    <measurement group_id="O3" value="206.10" lower_limit="188.53" upper_limit="225.31"/>
                    <measurement group_id="O4" value="178.30" lower_limit="166.36" upper_limit="191.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Pre-vaccination, N = 862, 853, 860, 1286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.77" lower_limit="17.29" upper_limit="20.38"/>
                    <measurement group_id="O2" value="20.56" lower_limit="18.89" upper_limit="22.38"/>
                    <measurement group_id="O3" value="18.37" lower_limit="16.88" upper_limit="19.99"/>
                    <measurement group_id="O4" value="19.99" lower_limit="18.65" upper_limit="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Post-vaccination, N = 862, 853, 860, 1284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.46" lower_limit="235.49" upper_limit="288.09"/>
                    <measurement group_id="O2" value="234.03" lower_limit="212.13" upper_limit="258.21"/>
                    <measurement group_id="O3" value="246.06" lower_limit="222.65" upper_limit="271.93"/>
                    <measurement group_id="O4" value="230.71" lower_limit="213.75" upper_limit="249.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Pre-vaccination, N = 862, 855, 860, 1286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.77" lower_limit="22.03" upper_limit="25.63"/>
                    <measurement group_id="O2" value="25.59" lower_limit="23.69" upper_limit="27.64"/>
                    <measurement group_id="O3" value="24.24" lower_limit="22.51" upper_limit="26.10"/>
                    <measurement group_id="O4" value="25.05" lower_limit="23.53" upper_limit="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Post-vaccination, N = 861, 856, 860, 1285)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.72" lower_limit="96.61" upper_limit="111.35"/>
                    <measurement group_id="O2" value="102.91" lower_limit="95.88" upper_limit="110.46"/>
                    <measurement group_id="O3" value="100.82" lower_limit="93.95" upper_limit="108.20"/>
                    <measurement group_id="O4" value="126.91" lower_limit="119.70" upper_limit="134.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved Seroconversion Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
        <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and post-vaccination titer of ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum of four-fold increase 28 days post-vaccination.</description>
        <time_frame>28 Days post-vaccination</time_frame>
        <population>Seroprotection was analyzed in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Lot 1</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 1 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intradermal (ID) Vaccine Lot 2</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 2 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Intradermal (ID) Vaccine Lot 3</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 3 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Intramuscular (IM) Vaccine</title>
            <description>Participants received a dose of Fluzone Intramuscular (IM) vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Seroconversion Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
          <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.
Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and post-vaccination titer of ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum of four-fold increase 28 days post-vaccination.</description>
          <population>Seroprotection was analyzed in the per-protocol population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="863"/>
                <count group_id="O2" value="856"/>
                <count group_id="O3" value="860"/>
                <count group_id="O4" value="1286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Serogroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Seroprotection Pre- and Post-vaccination With Either Fluzone ID or Fluzone IM</title>
        <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.
Seroprotection was defined as a HAI antibody titer ≥ 1:40.</description>
        <time_frame>Before and 28 Days post-vaccination</time_frame>
        <population>4-Fold increase in antibody levels were analyzed in h per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Lot 1</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 1 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intradermal (ID) Vaccine Lot 2</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 2 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Intradermal (ID) Vaccine Lot 3</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 3 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Intramuscular (IM) Vaccine</title>
            <description>Participants received a dose of Fluzone Intramuscular (IM) vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Seroprotection Pre- and Post-vaccination With Either Fluzone ID or Fluzone IM</title>
          <description>The serological determinations of anti influenza antibodies was by Hemagglutination Inhibition (HAI) assay.
Seroprotection was defined as a HAI antibody titer ≥ 1:40.</description>
          <population>4-Fold increase in antibody levels were analyzed in h per-protocol population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="863"/>
                <count group_id="O2" value="857"/>
                <count group_id="O3" value="861"/>
                <count group_id="O4" value="1287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Serogroup (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Serogroup (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Serogroup (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup (Pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Serogroup (Post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
        <description>Solicited injection site reactions: Ecchymosis, Erythema, Induration, Pain, Pruritus, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.</description>
        <time_frame>Day 0 up to 7 Days post vaccination</time_frame>
        <population>Safety analysis was on all enrolled and vaccinated participants, intend-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Intradermal (ID) Vaccine Lot 1</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 1 on Day 0</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Intradermal (ID) Vaccine Lot 2</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 2 on Day 0</description>
          </group>
          <group group_id="O3">
            <title>Fluzone Intradermal (ID) Vaccine Lot 3</title>
            <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 3 on Day 0</description>
          </group>
          <group group_id="O4">
            <title>Fluzone Intramuscular (IM) Vaccine</title>
            <description>Participants received a dose of Fluzone Intramuscular (IM) vaccine on Day 0</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions, Post Vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccine</title>
          <description>Solicited injection site reactions: Ecchymosis, Erythema, Induration, Pain, Pruritus, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering.</description>
          <population>Safety analysis was on all enrolled and vaccinated participants, intend-to-treat population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="953"/>
                <count group_id="O2" value="951"/>
                <count group_id="O3" value="951"/>
                <count group_id="O4" value="1421"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Injection Site Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Ecchymosis (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="716"/>
                    <measurement group_id="O2" value="698"/>
                    <measurement group_id="O3" value="726"/>
                    <measurement group_id="O4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Erythema (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="554"/>
                    <measurement group_id="O2" value="533"/>
                    <measurement group_id="O3" value="547"/>
                    <measurement group_id="O4" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Induration (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480"/>
                    <measurement group_id="O2" value="449"/>
                    <measurement group_id="O3" value="500"/>
                    <measurement group_id="O4" value="749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Pain (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447"/>
                    <measurement group_id="O2" value="430"/>
                    <measurement group_id="O3" value="438"/>
                    <measurement group_id="O4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Pruritus (Incapacitating)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection Site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544"/>
                    <measurement group_id="O2" value="525"/>
                    <measurement group_id="O3" value="519"/>
                    <measurement group_id="O4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection Site Swelling (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Solicited Fever (&gt; 102.2°F)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="279"/>
                    <measurement group_id="O3" value="314"/>
                    <measurement group_id="O4" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr 3 Solicited Headache- Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="202"/>
                    <measurement group_id="O3" value="239"/>
                    <measurement group_id="O4" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Solicited Malaise- Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252"/>
                    <measurement group_id="O2" value="229"/>
                    <measurement group_id="O3" value="260"/>
                    <measurement group_id="O4" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grd 3 Solicited Myalgia- Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gr 3 Solicited Shivering-Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination for up to 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluzone Intradermal (ID) Vaccine Lot 1</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 1 on Day 0</description>
        </group>
        <group group_id="E2">
          <title>Fluzone Intradermal (ID) Vaccine Lot 2</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 2 on Day 0</description>
        </group>
        <group group_id="E3">
          <title>Fluzone Intradermal (ID) Vaccine Lot 3</title>
          <description>Participants received a dose of Fluzone Intradermal (ID) vaccine Lot 3 on Day 0</description>
        </group>
        <group group_id="E4">
          <title>Fluzone Intramuscular (IM) Vaccine</title>
          <description>Participants received a dose of Fluzone Intramuscular (IM) vaccine on Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="953"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="951"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="951"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA10.0">Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Non cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Sepsi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Stent occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the gastrointestinal tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="953"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="953"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="951"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="716" subjects_at_risk="953"/>
                <counts group_id="E2" subjects_affected="698" subjects_at_risk="951"/>
                <counts group_id="E3" subjects_affected="726" subjects_at_risk="951"/>
                <counts group_id="E4" subjects_affected="749" subjects_at_risk="1421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site ecchymosis</sub_title>
                <counts group_id="E1" events="81" subjects_affected="81" subjects_at_risk="935"/>
                <counts group_id="E2" events="82" subjects_affected="82" subjects_at_risk="935"/>
                <counts group_id="E3" events="97" subjects_affected="97" subjects_at_risk="929"/>
                <counts group_id="E4" events="86" subjects_affected="86" subjects_at_risk="1392"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="716" subjects_affected="716" subjects_at_risk="936"/>
                <counts group_id="E2" events="698" subjects_affected="698" subjects_at_risk="935"/>
                <counts group_id="E3" events="726" subjects_affected="726" subjects_at_risk="930"/>
                <counts group_id="E4" events="184" subjects_affected="184" subjects_at_risk="1393"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="554" subjects_affected="554" subjects_at_risk="934"/>
                <counts group_id="E2" events="533" subjects_affected="533" subjects_at_risk="935"/>
                <counts group_id="E3" events="547" subjects_affected="547" subjects_at_risk="929"/>
                <counts group_id="E4" events="139" subjects_affected="139" subjects_at_risk="1392"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="480" subjects_affected="480" subjects_at_risk="936"/>
                <counts group_id="E2" events="449" subjects_affected="449" subjects_at_risk="935"/>
                <counts group_id="E3" events="500" subjects_affected="500" subjects_at_risk="931"/>
                <counts group_id="E4" events="749" subjects_affected="749" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="447" subjects_affected="447" subjects_at_risk="936"/>
                <counts group_id="E2" events="430" subjects_affected="430" subjects_at_risk="935"/>
                <counts group_id="E3" events="438" subjects_affected="438" subjects_at_risk="931"/>
                <counts group_id="E4" events="129" subjects_affected="129" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="544" subjects_affected="544" subjects_at_risk="934"/>
                <counts group_id="E2" events="525" subjects_affected="525" subjects_at_risk="935"/>
                <counts group_id="E3" events="519" subjects_affected="519" subjects_at_risk="929"/>
                <counts group_id="E4" events="117" subjects_affected="117" subjects_at_risk="1392"/>
              </event>
              <event>
                <sub_title>Solicited Malaise</sub_title>
                <counts group_id="E1" events="212" subjects_affected="212" subjects_at_risk="936"/>
                <counts group_id="E2" events="202" subjects_affected="202" subjects_at_risk="935"/>
                <counts group_id="E3" events="239" subjects_affected="239" subjects_at_risk="930"/>
                <counts group_id="E4" events="309" subjects_affected="309" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Myalgia</sub_title>
                <counts group_id="E1" events="252" subjects_affected="252" subjects_at_risk="936"/>
                <counts group_id="E2" events="229" subjects_affected="229" subjects_at_risk="935"/>
                <counts group_id="E3" events="260" subjects_affected="260" subjects_at_risk="930"/>
                <counts group_id="E4" events="430" subjects_affected="430" subjects_at_risk="1394"/>
              </event>
              <event>
                <sub_title>Solicited Shivering</sub_title>
                <counts group_id="E1" events="71" subjects_affected="71" subjects_at_risk="936"/>
                <counts group_id="E2" events="56" subjects_affected="56" subjects_at_risk="935"/>
                <counts group_id="E3" events="77" subjects_affected="77" subjects_at_risk="930"/>
                <counts group_id="E4" events="87" subjects_affected="87" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Headache</sub_title>
                <counts group_id="E1" events="282" subjects_affected="282" subjects_at_risk="936"/>
                <counts group_id="E2" events="279" subjects_affected="279" subjects_at_risk="935"/>
                <counts group_id="E3" events="314" subjects_affected="314" subjects_at_risk="930"/>
                <counts group_id="E4" events="422" subjects_affected="422" subjects_at_risk="1394"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

